Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; however, involvement of other sites such as the liver, gastrointestinal tract, joints, fascia, and lungs can occur alone or concurrently (LLS, 2022). In recent years, advances in the management of other HSCT–related complications such as cytomegalovirus and invasive fungal infections have led to substantial reductions in mortality (Rahi et al, 2021). Despite intensive research, GVHD remains a challenge due to its heterogeneity and complex pathogenesis (Malard et al, 2020). In this podcast, Shernan Holtan, MD, of the University of Minnesota and Carrie Kitko, MD, of Vanderbilt University Medical Center will explore new biomarkers used for diagnosis and therapy selection, discuss the latest clinical trial findings, and advise practitioners on how to individualize treatment to patients' needs.